What is Biobot Analytics?
Founded in 2017 by Mariana Matus and Newsha Ghaeli, Biobot Analytics operates at the intersection of biotechnology and data science. Headquartered in Cambridge, Massachusetts, the company utilizes proprietary molecular technologies and advanced AI algorithms to extract actionable insights from wastewater. This non-invasive, population-level monitoring provides municipalities and health organizations with real-time data, effectively serving as an early-warning system for public health threats. By transforming sewage into a diagnostic tool, Biobot Analytics has carved out a unique niche in the global health tech landscape, offering a scalable solution for disease surveillance that traditional clinical testing cannot match.
How much funding has Biobot Analytics raised?
Biobot Analytics has raised a total of $24.2M across 2 funding rounds:
Other Financing Round
$4.2M
Other Financing Round
$20M
Other Financing Round (2020): $4.2M with participation from DCVC Management Co LLC, The Engine, Y Combinator, and American Family Insurance
Other Financing Round (2021): $20M led by Thursday Ventures
Key Investors in Biobot Analytics
The Engine
The Engine, built by MIT, is a venture firm investing in the next generation of Tough Tech, applying cutting-edge technology to solve challenges in human health, climate change, and infrastructure.
Y Combinator
Established in 2005 and located in Mountain View, California, Y Combinator provides seed funding for startup businesses and acts as a premier accelerator for high-growth ventures.
American Family Insurance
American Family Insurance provides personal and business insurance products, offering strategic capital to support innovation in sectors that impact community health and safety.
What's next for Biobot Analytics?
With the recent injection of $0, Biobot Analytics is well-positioned to scale its operations and expand its footprint in the enterprise-level health market. The company is expected to focus on enhancing its AI-driven analytical capabilities and broadening its geographic reach to support more municipal and regional health departments. As the demand for proactive, data-backed public health strategies intensifies, Biobot's ability to provide granular, population-wide health data will likely drive further strategic partnerships and long-term growth. The firm remains committed to refining its molecular detection methods, ensuring that its platform remains the gold standard for wastewater-based epidemiology in an increasingly complex global health environment.
See full Biobot Analytics company page
